Athira Pharma (NASDAQ:LONA) Stock Rating Upgraded by Mizuho

Athira Pharma (NASDAQ:LONA) was upgraded by equities research analysts at Mizuho from a “neutral” rating to an “outperform” rating in a research report issued to clients and investors on Thursday, MarketBeat reports. The firm presently has a $10.00 price target on the stock. Mizuho’s price target would indicate a potential upside of 79.86% from the stock’s previous close.

A number of other equities research analysts also recently weighed in on the company. Wall Street Zen raised Athira Pharma to a “hold” rating in a report on Saturday, February 14th. Weiss Ratings assumed coverage on Athira Pharma in a research note on Wednesday, February 11th. They issued a “sell (d-)” rating on the stock. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $10.00.

Athira Pharma Price Performance

Shares of NASDAQ LONA opened at $5.56 on Thursday. Athira Pharma has a one year low of $2.20 and a one year high of $8.36.

About Athira Pharma

Athira Pharma, traded as LONA on the NASDAQ, is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapeutics intended to restore neuronal health and function in neurodegenerative and cognitive disorders. The company’s research approach centers on modulating pathways involved in synaptic repair and neurotrophic signaling to address underlying neuronal dysfunction rather than solely treating symptoms.

Athira’s lead investigational therapy is fosgonimeton (ATH-1017), a small-molecule candidate designed to potentiate hepatocyte growth factor (HGF)/MET pathway signaling with the aim of improving synaptic connectivity and cognitive performance in patients with conditions such as Alzheimer’s disease and related cognitive impairments.